TO THE EDITOR
p73 is a newly identified member of the p53 family, which was originally considered a candidate tumor suppressor gene. Unlike p53, p73 codes for several splicing variants (p73␣, ␤, ␥, ␦, ⑀, and ⌬exon2) which are differently expressed in normal cells and tumor cells. 1, 2 DNA damage induces p73 expression through the c-abl tyrosine kinase pathway. Interestingly, activation of c-abl oncogene is associated with chronic myelogenous and acute leukemias in humans. p73 might contribute to the development and progression of lymphoid neoplasms, since its expression is down-regulated by DNA methylation in acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma. 3, 4 In an attempt to understand the role of p73 expression in leukemias, we have determined the pattern of expression of this gene in 91 BALLs (7 pre-pre B-ALLs, 40 C-ALLs, 40 pre B-ALLs and 4 B-ALLs) and 39 T-ALLs. In the group of patients included in the study, overall p73 expression was approximately 60% with similar frequency in B-ALLs (61.5%) and T-ALLs (56.4%). The event-free survival among homogeneous subgroups of patients with p73 positive and negative leukemic cells was similar, which indicates that p73 expression is not of prognostic value. However, p73 may be a marker of differentiation in the leukemic process of child B cell ALL. Indeed, we detected the p73 transcript in 7/7 samples with a pre-pre B phenotype (CD10 negative) and in 49/80 cases of early B cells (CD10-positive C-ALL and pre-B-ALL), whereas p73 mRNA was not detectable in 4/4 mature B-ALLs (surface immunoglobulins positive, or restricted). These results indicate that p73 expression is significantly associated with early B-ALL (P = 0.005, Fisher's exact test).
Nested RT-PCR amplification of p73 mRNA from leukemic cells with a primer set encompassing exons 9 to 14 5,6 generated a series of fragments that could not be attributed to any of the known p73 splicing variants (␣-) (Figure 1a ). These products correspond to three up to now unidentified variants which we named p73, 1 and . p73 was detected in primary neuroblastomas and breast carcinoma cell line MCF7 but not in the B-lymphocytes derived from seven healthy donors. On the contrary, p731 and are also present in nontumor lymphocytes. p73 lacks exons 10, 11, 12 and 13 (Figure 1b) . This generates an in-frame deletion of 168 aminoacids followed by a -COOH tail of 110 residues identical to that of p73␣ (Figure 1c) . p731 results from the complete splicing of exons 10, 11 and 12; two nucleotides at the 3Ј-end of exon 9 are deleted, whereas the last 18 nucleotides of exon 13 are retained. In p73 exons 10, 11 and 13 are spliced out but exon 12 is retained (Figure 1b) . The splicings generating p731 and p73 result in frame-shifts leading to the translation of 5 (p731) and 17 (p73) amino acids followed by premature stop codons. The predicted -COOH terminus of p731 is almost identical to that of the ␥ isoform, whereas that of p73 does not share similarities with any known sequence (Figure 1c) . The result of the splicing of exon 10 in these new variants is the loss of the region of homology with the p53 oligomerization domain and of the transactivation domains at the -COOH terminus which are unique to p73␣ and ␤. It is thus likely that the activities of p73, 1 and are different from those of p73␣-.
The expression pattern of the various p73 variants in B-ALL shows remarkable characteristics. p73␦, p73, p731 and p73 were never observed in pre-pre B leukemias, whereas they were detectable in Correspondence: GP Tonini, Advanced Biotechnology Centre, L.go R Benzi, 10, 16132 Genoa, Italy; Fax: 39 010 5737463 The first two authors contributed equally to the work Received 29 September 1999; accepted 16 November 1999 approximately 10-20% of pre B ALLs and C-ALLs. The significance of the different p73 variant expression is therefore under study. Conclusively, our results show that expression of these p73 isoforms is restricted to more differentiated B-ALL subgroups. We did not observe significant differences in the pattern of p73 expression in T-ALL subgroups subdivided according to their immunophenotypes (pre-T, intermediate and mature). The lack of p73 expression in mature B-ALL suggests that the loss of p73-related apoptotic mechanisms may contribute to the high proliferation rate characteristic of these lymphoproliferative disorders. Moreover the different isoforms may lead to the differentiation process of B-ALL cells. 
